Company

Bio-Rad Laboratories Inc.

BIOLife Sciences Tools and Services

Bio-Rad Laboratories Inc. is a leading provider of life science research and clinical diagnostic products, founded in 1952 and headquartered in Hercules, California, United States.

Snapshot

Bio-Rad Laboratories Inc. is a life sciences tools and services company that has completed 11 disclosed acquisitions and reported $2.58B in latest-year revenue.

Sector
Life Sciences Tools and Services
Ticker
BIO
Revenue (LTM)
$2.58B
Acquisitions
11
Operating margin
1.8%
Latest call
Q1 2026

Business description

Bio-Rad Laboratories Inc. is a leading provider of life science research and clinical diagnostic products, founded in 1952 and headquartered in Hercules, California, United States. The company generates revenue through advanced laboratory instruments, reagents, and software sold to research institutions, hospitals, and biopharma companies. Under the leadership of CEO Norman H. Schwartz, Bio-Rad continues to drive innovation with flagship products including the GelDoc and Bio-Plex systems. With strategic investments in digital automation and next-generation diagnostics, the firm is well-positioned for sustained global growth.

$2.58B
Revenue (LTM)
11
Acquisitions
1.8%
Operating margin
Q1 2026
Latest call

Financials

View financials
Revenue (FY2025) $2.58B
YoY growth +0.7%
Operating margin 1.8%
Direction Expanding
Gross margin 51.9%
Net margin 29.4%

Leadership & board

View leadership

Share repurchases

Bio-Rad's board authorized the 2023 Share Repurchase Program to repurchase up to $1.0 billion of common stock (a $500 million authorization in July 2023 plus an additional $500 million in July 2024), with $284.6 million remaining available as of December 31, 2025.

$1.0 billion (2023 Share Repurchase Program: $500 million authorized in July 2023, plus an additional $500 million authorized in July 2024)
Authorized
$284.6 million (as of December 31, 2025)
Remaining
$295.5 million (payments for purchases of treasury stock, year ended December 31, 2025)
Repurchased (latest FY)

Competition & customers

Named competitors
Becton DickinsonDanaherMerck KGaAQiagen N.V.Thermo Fisher ScientificAbbott LaboratoriesbioMerieuxDiaSorinWerfenQuidelOrthoRocheSiemens Healthineers+1 more

Recent SEC filings

View on EDGAR
2026-04-30 Reported quarterly results (+1 more) View filing ↗
2026-04-24 Leadership change (directors/officers) (+1 more) View filing ↗
2026-02-19 Regulation FD disclosure View filing ↗
2026-02-12 Reported quarterly results (+1 more) View filing ↗
2025-10-29 Reported quarterly results (+1 more) View filing ↗
2025-09-30 Regulation FD disclosure View filing ↗
2025-08-26 Regulation FD disclosure View filing ↗
2025-07-31 Reported quarterly results (+1 more) View filing ↗
2025-07-28 Leadership change (directors/officers) (+1 more) View filing ↗
2025-06-30 Other event View filing ↗
2025-05-01 Reported quarterly results View filing ↗
2025-04-25 Shareholder vote results View filing ↗
SourcesSEC filings · company financials · earnings transcripts Last updated

See how VectorShift works for your firm

Request Demo